Oppenheimer initiates Lexeo Therapeutics stock with Outperform rating

Published 31/07/2025, 12:14
Oppenheimer initiates Lexeo Therapeutics stock with Outperform rating

Investing.com - Oppenheimer initiated coverage on Lexeo Therapeutics (NASDAQ:LXEO) with an Outperform rating and a price target of $20.00 on Thursday. The stock, currently trading at $4.65, has shown strong momentum with a 26.7% gain over the past week. According to InvestingPro data, analyst targets range from $10 to $28, suggesting significant upside potential.

The research firm expressed optimism about Lexeo’s development of gene therapies for rare cardiac and neurodegenerative diseases, highlighting the company’s lead candidate LX2006, which is advancing to a registration trial for Friedreich’s ataxia cardiomyopathy.

Oppenheimer estimates that LX2006 could achieve over $1 billion in peak sales in the U.S. market, citing previous clinical data that indicates a clear path to success for the therapy.

The firm also noted Lexeo’s second candidate, LX2020, which targets PKP2 arrhythmic cardiomyopathy and represents a potentially larger market opportunity, with important data expected this fall that could clarify its path to market.

Oppenheimer stated that Lexeo’s technology offers advantages in efficacy, safety, and scalability compared to other gene therapy approaches. With a cash runway extending into 2028 and a market capitalization of $251 million, the firm recommends investors build a position in the stock. InvestingPro analysis shows the company maintains a healthy current ratio of 3.42, with liquid assets exceeding short-term obligations, though it’s currently burning through cash with negative free cash flow of $88.3 million.

In other recent news, Lexeo Therapeutics announced that the U.S. Food and Drug Administration granted Breakthrough Therapy designation to its LX2006 treatment for Friedreich ataxia. This designation was based on interim clinical data showing improvements in cardiac biomarkers and functional measures. Additionally, the FDA selected LX2006 for its Chemistry, Manufacturing, and Controls Development and Readiness Pilot program to expedite development timelines. Stifel has reiterated its Buy rating on Lexeo Therapeutics with a $21 price target following this announcement. Meanwhile, Leerink Partners adjusted its price target for Lexeo to $10, down from $16, while maintaining an Outperform rating, as the company entered into a private placement agreement expected to raise approximately $80 million. This agreement involves the sale of common shares and warrants, potentially extending Lexeo’s cash runway into 2028. Lexeo also held its 2025 Annual Meeting of Stockholders, where two Class II directors were elected, and the selection of its independent registered public accounting firm was ratified.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.